Looking for new opportunities after a strategic reorganization at my previous employer - and using this gap as a great opportunity to catch up on science news!

• Led a team of 6 scientists and associates, contributing to multiple small molecule programs aimed at selective inhibition of nascent chain - ribosome complexes• Responsible for PD biomarker assessment and SAR assay development and execution – Key contributor to exploration of biomarker hypotheses, support of indication selection, and combination therapy planning – Guided strategic planning, execution, and interpretation of preclinical mouse model tumor PD analysis – Ensured that SAR assay support was fit for purpose, with reproducible weekly data for lead optimization & selection – Project team biology representative for 2 preclinical small molecule programs – Created new communication channels for interaction with Ribosome Biology and In Vivo Pharmacology groups – Responsibilities included novel in-house assay development, in vivo model analysis, hypothesis generation, communication of results to project teams and executive leadership

• Led a team of 4 scientists (3 direct reports) to support translational research for Probody therapeutics (Pb-Tx; novel masked biologics that are selectively activated in the tumor)• Accountable for in-house and outsourced biomarker assays and translational in vivo models / MOA studies for 4 clinical-stage programs covering a range of therapeutic modalities (Pb-Tx, Pb-drug-conjugate, Pb-bispecific) – Responsibilities included CRO management, novel in-house assay development and qualification, in vivo model selection and study design, data analysis, hypothesis generation, communication of results to project teams• Translational project team representative for 3 late-stage preclinical programs: developed and implemented predictive and/or PD biomarker strategy for preclinical and clinical samples; transitioned one of the 3 pre-IND programs to Phase 1 • Contributed biomarker sections for clinical protocol (and other associated documents) for 3 programs• Designed and implemented granular strategy to identify exploratory predictive and PD biomarkers in preclinical and clinical samples, using unbiased and biased approaches (proteomics, genomics, transcriptomics, targeted platforms)• Developed novel Pb-Tx activation assay to generate the first “proof of platform” data demonstrating tumor-selective unmasking of Pb-Tx in patients• Worked cross-functionally with Research, Clinical Development, Clinical Operations, Clinical Data Management, Biometrics, and Regulatory / Medical Writing• Lead author on 2 posters; contributing author on 2 papers and 1 poster

• Leader of 5-member biology core team for assessment of early-stage small molecule oncology target; successfully demonstrated preclinical proof-of-concept validation (in vitro and in vivo) – Profiled sensitivity to novel inhibitor in >75 cell lines using 3D tissue culture and clonogenic survival assays; demonstrated key proof-of-concept oncogene sensitivity correlation • Co-led translational research for anti-MMP9 therapeutic antibody and contributed to successful IND filing: – Responsible for model evaluation, study design, CRO coordination, and analysis of >20 in vivo studies – Contributed to indication selection strategy by carrying out an extensive literature survey to assess correlation of MMP9 levels with survival and recurrence in 15 solid tumor types – Co-first author on manuscript assessing efficacy and MOA of anti-MMP9 antibodies in mouse models of cancer and inflammation• Developed, optimized, and executed biomarker assays for the anti-LOXL2 clinical program - Generated patient sample data establishing LOXL2 as a correlative biomarker for the severity of fibrotic disease - Contributing author on 4 posters and 2 papers for LOXL2 program

• Coordinated team of 7 researchers for phenotypic characterization of XL888 (small-molecule HSP90 inhibitor); acted as liaison between XL888 teams in Biology and in Translation Medicine:– Developed novel high-content, high-throughput cell cycle analysis assay using the Cellomics imaging platform, allowing precise identification of all 4 phases and providing high-resolution data on the effects of HSP90 inhibitors on cell growth– First author on manuscript demonstrating utility of Cellomics cell cycle assay in preclinical characterization of XL888• Led a team of 3 colleagues in screening of ~40,0000 siRNA library to detect Myc-induced apoptosis phenotypes and identify novel oncology drug targets– Contributed substantially to screening benchwork, analyzed and compiled data, devised data-handling protocols and hit stratification strategies– Prepared proposals and recommendations for target validation of top screen hits, resulting in advancement of a small-molecule screening campaign for one target

- Designed and executed analyses of cellular function using “reverse transfection” microarray technology to interrogate small molecule effects on tyrosine kinases, MAP kinases, and cell cycle checkpoints- Published 1 paper